X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
India's drug regulator approved antiviral medication Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for restricted emergency use against Covid-19 amid rising infections in the country.
Lead Product(s): Ritonavir,Nirmatrelvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Paxlovid
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2022
Details:
Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorization by local regulatory agencies.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: MK-4482
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 27, 2021
Details:
Hetero announced today that it has received the manufacturing and marketing approval for the investigational antiviral medicine ‘Remdesivir’ from the Drug Controller General of India (DCGI) for the treatment of Covid-19.
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Covifor
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
